

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NICE guidelines

Equality and health inequalities assessment (EHIA)

Ectopic pregnancy and miscarriage (update)

The considerations and potential impact on equality and health inequalities have been considered throughout the guidance development, maintenance and update process according to the principles of the NICE equality policy and those outlined in [Developing NICE guidelines: the manual](#).

This EHIA relates to:

The use of anti-D prophylaxis in pregnant people with a threatened miscarriage, miscarriage or ectopic pregnancy in the first trimester.

STAGE 2. Informing the scope

(to be completed by the Developer, and submitted with the draft scope for consultation, if this is applicable)

Ectopic pregnancy and miscarriage

Date of completion: 16th June 2025

Focus of guideline or update: The use of anti-D rhesus prophylaxis in pregnant people with a threatened miscarriage, miscarriage or ectopic pregnancy in the first

For short updates where there is no scoping workshop or scope consultation, questions relating to these in stage 2 can be noted 'not applicable'.

2.1 What approaches have been used to identify potential equality and health inequalities issues during the check for an update or during development of the draft scope?

Equalities impact assessments were undertaken for the guideline updates in 2023, 2021, and the original guideline in 2019.
--

Information on equality and health inequalities was identified via non-systematic literature searches and through discussion with topic experts.
--

2.2 What potential equality and health inequalities issues have been identified during the check for an update or during development of the draft scope?
--

Anti-D immunoglobulin is a blood product; some faith groups do not allow the receipt of blood products.

Geographical location and proximity of services could lead to barriers to people accessing anti-D prophylaxis.
--

Some groups of people may need to return to hospital for anti-D prophylaxis; this may be complicated by their geographical location (or that of the service provider), the cost of attending services (socioeconomic factors) or caring responsibilities, for example.

2.3 How can the identified equality and health inequalities issues be further explored and considered at this stage of the development process?

The committee will consider specific issues relating to inequalities noted in section 2.2 in their discussions on the use of anti-D prophylaxis.

2.4 Do you have representation from stakeholder groups that can help to explore equality and health inequalities issues during the consultation process including groups who are known to be affected by these issues? If not, what plans are in place to address gaps in the stakeholder list?

Not applicable as no consultation is planned.

2.5 How will the views and experiences of those affected by equality and health inequalities issues be meaningfully included in the guideline development process going forward?

The guideline committee has members with lived experience of women's and reproductive health issues. We are aware that experience of receiving anti-D prophylaxis is a very specific issue and therefore we will discuss other ways that views and experiences of those affected by equality and health inequalities issues can be involved with the people and communities team. We will ensure that relevant stakeholders are registered to comment on the draft guideline recommendations.

2.6 If applicable, what questions will you ask at the draft scope stakeholder consultation about the guideline/update and potential impact on equality and health inequalities?

Not Applicable

2.7 Has it been proposed to exclude any population groups from the scope? If yes, how do these exclusions relate to any equality and health inequalities issues identified?

Not proposed to exclude any population groups from the scope.

Completed by developer: Sara Buckner

Date: 16th June 2025

Approved by committee chair: Sarah Fishburn

Date: 26th August 2025

Approved by NICE quality assurance lead: Kate Kelley

Date: 2nd July 2025